Yamamoto, Nobuyuki
Hayashi, Hidetoshi
Planchard, David
Morán, Teresa
Gregorc, Vanesa
Dowell, Jonathan
Sakai, Hiroshi
Yoh, Kiyotaka
Nishio, Makoto
Cortot, Alexis B.
Benhadji, Karim A.
Soni, Nital
Huang, Jinhong
Makris, Lukas
Cedres, Susana
Funding for this research was provided by:
Taiho Oncology, Inc.
Taiho Pharmaceutical Co.
Article History
Received: 26 February 2020
Accepted: 20 March 2020
First Online: 3 April 2020
Compliancewith ethical standards
:
: N. Yamamoto has received grants and/or personal fees from Taiho Pharmaceutical. H. Hayashi has received grants and personal fees from AstraZeneca, Boehringer Ingelheim Japan, Bristol-Myers Squibb, Chugai Pharmaceutical, Eli Lilly Japan, MSD, Ono Pharmaceutical, Pfizer Japan, and Taiho Pharmaceutical. D. Planchard has participated in consulting, acted in an advisory role, and received lecture fees from AstraZeneca, Bristol-Myers Squibb, Boehringer Ingelheim, Celgene, Merck, Novartis, Pfizer, Roche, prIME Oncology, and Peer CME, and has worked as a principal or co-investigator for clinical trial research for AstraZeneca, Bristol-Myers Squibb, Boehringer Ingelheim, Daiichi Sankyo, Eli Lilly, MedImmune, Merck, Novartis, Novocure, Pfizer, Roche, Sanofi-Aventis, and Taiho Pharmaceutical. H. Sakai has received personal fees from Taiho Pharmaceutical. K. Yoh has received grants and/or personal fees from AstraZeneca, Bayer, Boehringer Ingelheim, Bristol-Myers Squibb, Chugai Pharmaceutical, Eli Lilly Japan, MSD, Novartis, Ono Pharmaceutical, Pfizer, and Taiho Pharmaceutical. M. Nishio has received grants and/or non-financial support from F. Hoffmann-La Roche and grants and/or personal fees from Astellas, AstraZeneca, Boehringer Ingelheim, Bristol Myers Squibb, Chugai Pharmaceutical, Eli Lilly, Merck Serono, MSD, Novartis, Ono Pharmaceutical, Pfizer, Sankyo Healthcare, and Taiho Pharmaceutical. A. Cortot has received grants, personal fees, and/or non-financial support from Astra-Zeneca, Bristol Myers Squibb, Merck, MSD, Novartis, Pfizer, Roche, and Takeda. KA Benhadji and N. Soni are employees of Taiho Oncology Inc. J. Huang is an employee of Taiho Pharmaceutical and owns Taiho Pharmaceutical stock. L. Makris has received personal fees from Taiho Oncology, Inc. S. Cedres has served in a consulting or an advisory role for Bristol-Myers Squibb, F. Hoffmann-La Roche AG, Pfizer, Boehringer Ingelheim, MSD Oncology, and Amphera; and has received travel and accommodation funding from F. Hoffmann-La Roche AG, Pfizer, and Boehringer Ingelheim. T. Morán, V. Gregorc, and J. Dowell have no conflicts of interest to disclose.
: The study was approved by independent ethics committees or institutional review boards at each site.
: All patients provided written informed consent before enrollment.
: All patients provided written informed consent for publication before enrollment.
: All statistical analyses were performed using SAS software version 9.4 in the UNIX environment (SAS Institute Inc., North Carolina, USA).
: All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.
: Informed consent was obtained from all individual participants included in the study.